Oramed Pharmaceuticals Inc: Initiation of Coverage

Oramed Pharmaceuticals Inc. develops an orally ingestible capsule for the delivery of protein-based therapies with focus on treatment of diabetes. The company advances two independent clinical programs: ORMD-0801 – an oral insulin product, and ORMD-0901 – an oral GLP-1 receptor agonist product, both targeted at the immense type 2 diabetes market. In addition, Oramed is developing a combination product of ORMD-0801+0901 and has out-licensed a different oral protein delivery technology to a 3rd party for development of an osteoporosis treatment.

For a copy of the report, fill out your details below. The link to the document will be sent to you when you click “Get the link”


Your name (required)

Your company (required)

Position (required)

Industry (required):

Country (required)

Your email (required)